PTEN and chronic myelogenous leukemia, BCR-ABL1 positive: Zhou et al. demonstrated the EZH2 inhibition-mediated beneficial effects on leukemia cells and prolonged survival of CML mice were compromised by the concurrent transduction of shRNA targeting PTEN [68].